Molecular Monitoring of Therapeutic Milestones and Clinical Outcomes in Patients With Chronic Myeloid Leukemia

Cancer - United States
doi 10.1002/cncr.31835
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Medication Adherence, Molecular Monitoring, and Clinical Outcomes in Patients With Chronic Myelogenous Leukemia in a Large HMO

Journal of the American Pharmacists Association : JAPhA
PharmacologyPharmacy
2017English

Does the Frequency of Molecular Monitoring After Tyrosine Kinase Inhibitor Discontinuation Affect Outcomes of Patients With Chronic Myeloid Leukemia?

Cancer
Cancer ResearchOncology
2017English

New Tool for Monitoring Molecular Response in Chronic Myeloid Leukemia.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Molecular Monitoring of Residual Disease in Chronic Myeloid Leukemia by Genomic DNA Compared With Conventional mRNA Analysis

Journal of Molecular Diagnostics
Forensic MedicinePathologyMolecular Medicine
2009English

Effect of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia (Cytogenetic, Molecular Response) in Mosul

Annals of the College of Medicine, Mosul
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy